#regorafenib

Live, measured metrics for the hashtag #regorafenib from the open social web. Every number carries a named source and the time it was fetched. Nothing is estimated.

hashtag.org network · sponsored

Own #regorafenib

This #name is available to claim. It becomes your portal on the open agent web: this very page, a keyword you rank for by an open public stake, and a verifiable identity for AI agents. Nobody else sells a page like this for every #name.

$10.85/ year · 11-character #name
Claim #regorafenib$10.85/yrBuy on hashtag.space (web3)
card via hashtag.org · tokens via hashtag.space
0
Uses / 7 days
Mastodon
0
Accounts / 7 days
Mastodon
1
Recent posts
Mastodon
Recent pace
Mastodon · last 1
0
Avg reactions / post
Mastodon · last 1
Reddit posts / month
Reddit search
Open-web mentions
hashtag.org Firehose

Day-by-day usage

measured · fosstodon.org (Mastodon public tags API) · fetched 2026-08-12 03:37 UTC
0
08-06
0
08-07
0
08-08
0
08-09
0
08-10
0
08-11
0
08-12

0 uses by 0 unique accounts across the window. Real per-day counts, not estimates. Newest bar is today so far.

Related hashtags

measured · fosstodon.org (Mastodon public search API) · fetched 2026-08-12 03:37 UTC

No related tags with measured usage found for #regorafenib.

Live pulse

measured · fosstodon.org (Mastodon tag timeline) · fetched 2026-08-12 03:37 UTC

Everything below is measured over the latest 1 public posts.

Posting hours (UTC)

00:0012:0023:00

Languages: English (1)

Avg boosts / post: 0

Top of the latest posts

  • The Raf #kinase #inhibitors #Dabrafenib and #Regorafenib impair #Zika virus #replication via distinct mechanisms, J Virol.: https://journals.asm.org/doi/full/10.1128/jvi.00618-24?af=R This study provides further insight into ZIKV-host inter

    Giuseppe Michieli@[email protected]002024-07-18 16:23 UTCView post →

What “regorafenib” means

Wikipedia

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had two US approvals for advanced cancers.

Regorafenib” on Wikipedia (CC BY-SA) →

#regorafenib across platforms

every network with a public tag surface

Follow #regorafenib straight to each platform’s own tag page. Where a platform publishes open data we measure it above; the rest lock their numbers behind paid APIs, so we link rather than guess.

Every number above is measured from a named public API at the shown fetch time. Nothing is estimated or extrapolated. Platforms that lock their data behind paid APIs are not shown. Agents: the same numbers, as JSON, at /api/hashtags/regorafenib